Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

During the past 5 years, better understanding of immunomodulatory and anti-angiogenesis properties of thalidomide has increased interest in the use of this agent for a wider variety of clinical applications. This article reviews the clinical evaluation of thalidomide for treatment or prevention of chronic graft-versus-host-disease.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Leuk Lymphoma

Title: Leukemia & lymphoma

Publisher: Informa UK Limited

ISSN: 1042-8194

ISSN (Print): 1026-8022

Publication date (Electronic): Jul 2003

Volume: 44

Issue: 7

Affiliations

[1 ] Division of Clinical Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., DS-290, PO Box 19024, Seattle, WA 98109-1024, USA. mflowers@fhcrc.org

Article

DOI: 10.1080/1042819031000079096

PubMed ID: 12916865

SO-VID: ce3cf8d6-f997-4b76-9786-dfdf1cb09e40

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Cited by 4

See all cited by